Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.

As part of the funding, Latent Labs aims to leverage generative artificial intelligence to computationally create novel ...

Robert F. Kennedy Jr. will serve as Secretary of Health and Human Services. 1 The US Senate voted 52-48 in favor of Kennedy ...

Evrysdi is a non-invasive, disease-modifying option that can be swallowed whole or dispersed in water for patients with ...

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be ...

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

In a recent article titled “ Big Pharma says ‘Thanks, but No Thanks’ to their own HEOR groups, ” Professor Scott Ramsey from ...

Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients ...

In this part of his Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, identifies strategies ...

In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI ponders the next big developments and breakthroughs he expects to see in the ...

Statistically significant means there is a very high likelihood the drug impacted its target. But if data are not clinically ...

The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.